Targeted alpha therapy (TAT) for treatment of various kinds of cancer relies on the idea of linking α-particle-emitting radionuclides to carrier molecules, which are tumor selective. Alpha-zirconium phosphate (α-ZrP) is a non-cytotoxic inorganic ion exchange material with a composition of Zr(HPO4)2●H2O that is stable under biological conditions. The particle shape of α-ZrP is platelet-like, which, compared to spherically shaped particles, should show better adhesion, margination, and binding properties. Combined, the particle size, shape, and ion-exchange intercalation chemistry make α-ZrP very attractive for radionuclide delivery for TAT. The loading and kinetics of uptake for α-ZrP have been investigated with ions relevant to TAT, specifically those in the 225Ac decay-chain, natural Cs+ (as a surrogate for 221Fr), natural Bi3+ (as a surrogate for 213Bi), and natural La3+ (as a surrogate for 225Ac). Results of these studies, including ion exchange kinetics, loading capacity, and leaching of the loaded material will be discussed.

Zirconium phosphate nano-platelets: A potential drug delivery vehicle for Ac-225

ACS Spring 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.